Coherus (CHRS) - התחייבויות לטווח ארוך להון

This daily price chart for Coherus Biosciences (CHRS) reflects the asset's dynamics, with a value of 0.80. Coherus Biosciences minimizes the environmental impact of chemical synthesis by implementing carbon controls and closed-loop water recycling. Business revenues are based on the sales of Loqtorzi and Udenyca biosimilars, while a network of specialized warehouses with precise inventory management ensures seamless deliveries to medical centers.

Analyzing the operational scale of Coherus Biosciences (CHRS) through the long-term debt-to-equity ratio allows for an assessment of the company's financial resilience against regulatory risks and raw material supply disruptions. This metric is calculated as the proportion of loans with maturities exceeding one year relative to equity, demonstrating the business's reliance on borrowed funds and the risk of declining profitability during periods of market stagnation.